Sun Pharmaceutical Industries Ltd, based in India, is a pharmaceutical company that stands out with its certifications from FDA, EDQM and WHO-GMP.
One of their notable products is LENVATINIB MESYLATE, with a corresponding US DMF Number 33331.
Remarkably, this DMF maintains an Active status since its submission on February 04, 2019, highlighting commitment to regulatory compliance.
Their GDUFA DMF Review was successfully complete, with a review date of March 27, 2019, and payment made on December 12, 2018, indicating their dedication to facilitating drug approvals, Categorized as Type II